{"id":"beacopp-escalated","safety":{"commonSideEffects":[{"rate":"70-90","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"60-80","effect":"Nausea and vomiting"},{"rate":"40-60","effect":"Mucositis"},{"rate":"80-90","effect":"Alopecia"},{"rate":"30-50","effect":"Infection"},{"rate":"5-15","effect":"Cardiotoxicity"},{"rate":"5-10","effect":"Secondary malignancy (long-term)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BEACOPP escalated is an intensified polychemotherapy combination used primarily in Hodgkin lymphoma. The regimen works through multiple mechanisms: alkylating agents (cyclophosphamide, procarbazine) cross-link DNA, topoisomerase inhibitors (etoposide) prevent DNA repair, anthracyclines (doxorubicin) intercalate DNA and generate reactive oxygen species, and vinca alkaloids (vincristine) disrupt microtubule formation. The 'escalated' designation refers to dose intensification compared to standard BEACOPP.","oneSentence":"BEACOPP escalated is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at escalated doses to kill rapidly dividing cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:44.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma, advanced stages (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT03159897","phase":"PHASE3","title":"FIL Study on ABVD DD-DI as Upfront Therapy in HL.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2017-08-01","conditions":"Hodgkin Lymphoma","enrollment":500},{"nctId":"NCT00049595","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-08","conditions":"Lymphoma","enrollment":552},{"nctId":"NCT02661503","phase":"PHASE3","title":"HD21 for Advanced Stages","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2016-07","conditions":"Classical Hodgkin Lymphoma","enrollment":1500},{"nctId":"NCT00678327","phase":"PHASE3","title":"Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University College, London","startDate":"2008-08-29","conditions":"Lymphoma","enrollment":1202},{"nctId":"NCT06263530","phase":"","title":"Prognostic Significance of ctDNA in HL","status":"RECRUITING","sponsor":"Interni hematologicka klinika FNKV","startDate":"2022-01-02","conditions":"Prognostic Cancer Model","enrollment":500},{"nctId":"NCT00822120","phase":"PHASE2","title":"S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2009-07","conditions":"Lymphoma, Nonneoplastic Condition","enrollment":371},{"nctId":"NCT01118026","phase":"PHASE2","title":"Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-09","conditions":"Lymphoma","enrollment":101},{"nctId":"NCT02298283","phase":"PHASE2","title":"Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2015-04","conditions":"Hodgkin Lymphoma","enrollment":40},{"nctId":"NCT00433433","phase":"PHASE3","title":"Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2006-10","conditions":"Lymphoma","enrollment":1952},{"nctId":"NCT00515554","phase":"PHASE3","title":"HD18 for Advanced Stages in Hodgkins Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2008-05","conditions":"Hodgkins Lymphoma","enrollment":1500},{"nctId":"NCT00795613","phase":"PHASE2","title":"Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)","status":"UNKNOWN","sponsor":"Ospedale Santa Croce-Carle Cuneo","startDate":"2008-06","conditions":"HODGKIN LYMPHOMA","enrollment":450},{"nctId":"NCT01251107","phase":"PHASE3","title":"Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2000-03","conditions":"Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT01304849","phase":"NA","title":"Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes","status":"COMPLETED","sponsor":"Cancer Institute WIA","startDate":"2011-01","conditions":"Hodgkin's Lymphoma","enrollment":50},{"nctId":"NCT00392314","phase":"PHASE2","title":"Tailored Therapy for Hodgkin Lymphoma Using Early Interim Therapy PET for Therapy Decision.","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2006-10","conditions":"Hodgkin Lymphoma","enrollment":365},{"nctId":"NCT00305149","phase":"NA","title":"Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"1999-07","conditions":"Classical Hodgkin Lymphoma, Nodular Sclerosis, Mixed Cellularity","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BEACOPP escalated","genericName":"BEACOPP escalated","companyName":"University of Cologne","companyId":"university-of-cologne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BEACOPP escalated is a multi-drug chemotherapy regimen that combines bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone at escalated doses to kill rapidly dividing cancer cells. Used for Hodgkin lymphoma, advanced stages (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}